Amikacin in the Treatment of Gram-Negative Bronchopulmonary Infections

Six patients with acute gram-negative bronchopulmonary infection were treated with amikacin (15 mg/kg per day) administered intramuscularly in two equal doses at 12-hr intervals for 10–13 days. Two patients had underlying nonspecific pulmonary disease, two had advanced bronchocarcinoma, and two had...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1976-11, Vol.134 (Supplement-2), p.S391-S393
Main Authors: Van Der Straeten, M., Pauwels, R., Pijck, J., Van Nimmen, L, Kluyskens, P., Soep, H.
Format: Article
Language:English
Subjects:
Acute Disease
Adult
Aged
Amikacin - adverse effects
Amikacin - blood
Amikacin - therapeutic use
Blood
Dosage
Enterobacteriaceae Infections - drug therapy
Eschatology
Haemophilus Infections - drug therapy
Haemophilus influenzae
Humans
Infections
Injections
Kanamycin - analogs & derivatives
Lung diseases
Middle Aged
Nystagmus
Pseudomonas Infections - drug therapy
Respiratory Tract Infections - blood
Respiratory Tract Infections - drug therapy
Sputum
University hospitals
Urine
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Six patients with acute gram-negative bronchopulmonary infection were treated with amikacin (15 mg/kg per day) administered intramuscularly in two equal doses at 12-hr intervals for 10–13 days. Two patients had underlying nonspecific pulmonary disease, two had advanced bronchocarcinoma, and two had extensive bronchiectasis (due to chronic aspergillosis in one patient). The pathogens were Pseudomonas aeruginosa in three patients, and Haemophilus inilucnzae, Klebsiella ozaenae, and Enteiobacter cloacae each in one patient. Five patients recovered completely, with resolution of fever and other acute symptoms and elimination of the causative organism from sputum cultures. A moribund patient with advanced metastatic bronchocarcinoma died two days after the treatment with amikacin had been completed; the last specimen of sputum was still positive for P. aeruginosa. Tests of liver and renal function and blood counts revealed no abnormalities. Complete audiometric survey showed no hearing loss. Nystagmography revealed reversible, lessened caloric response in some patients. Amikacin was well absorbed from the site of intramuscular injection. Levels of amikacin in serum varied among the subjects and, in some cases, for individual patients on different days.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/135.Supplement_2.S391